Publications by authors named "Marcus Neubauer"

Claim this Profile
I
Impact of an Oncology Clinical Pharmacist Intervention on Clinical Trial Enrollment in The US Oncology Network's MYLUNG Consortium.
Elizabeth Koselke, Lisa C Kaspin-Powell, Shannon Hough, Joshua Howell, Nicholas J Robert, Marcus A Neubauer

J Adv Pract Oncol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Closing the Testing Gap: Standardization of Comprehensive Biomarker Testing for Metastatic Non-Small-Cell Lung Cancer in a Large Community Oncology Practice.
David M Waterhouse, Patrick Ward, Suzzette Arnal, Marcus Neubauer, David R Drosick

JCO Oncol Pract· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in The US Oncology Network.
Nicholas J Robert, Janet L Espirito, Liwei Chen, Esmond Nwokeji, Mandar Karhade, Marcus Neubauer

Lung Cancer· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Affirming the Value of Clinical Chemotherapy Pathways Programs.
J Russell Hoverman, Aimee Ginsburg, Lalan Wilfong, Marcus Neubauer

JCO Oncol Pract· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Telemedicine in Community Cancer Care: How Technology Helps Patients With Cancer Navigate a Pandemic.
Debra A Patt, Lalan Wilfong, Sara Toth, Stephanie Broussard, Kristen Kanipe, Marcus Neubauer

JCO Oncol Pract· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Uncertainty from COVID-19 delays progress on the road to value-based cancer care.
Marcus Neubauer, Ben Jones

Am J Manag Care· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hospice or Hospital: The Costs of Dying of Cancer in the Oncology Care Model.
J Russell Hoverman, B Brooke Mann, Sara Phu, Philip Nelson, Jad E Hayes, Marcus A Neubauer

Palliat Med Rep· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Practice Patterns Among Oncologists Participating in the Oncology Care Model.
Brigham Walker, Jennifer Frytak, Jad Hayes, Marcus Neubauer, Nicholas Robert

JAMA Netw Open· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical pathways: reducing costs and improving quality across a network.
Marcus Neubauer

Am J Manag Care· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Centers for Medicare & Medicaid Services Oncology Care Model Halfway Through: Perspectives from Diverse Participants.
Ronald M Kline, Michelle Brown, Nikolas Buescher, John Cox, Elizabeth Horenkamp, Marcus Neubauer

J Natl Cancer Inst· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Redefining Quality Measurement in Cancer Care.
Elizabeth A Nardi, James McCanney, Katy Winckworth-Prejsnar, Alyssa A Schatz, Kerin Adelson, Marcus Neubauer

J Natl Compr Canc Netw· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Three-Year Results of a Medicare Advantage Cancer Management Program.
J Russell Hoverman, Marcus A Neubauer, Melissa Jameson, Jad E Hayes, Kathryn J Eagye

J Oncol Pract· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ixabepilone and Carboplatin for Hormone Receptor Positive/HER2-neu Negative and Triple Negative Metastatic Breast Cancer.
Cynthia Osborne, Jagathi D Challagalla, Charles F Eisenbeis, Frankie Ann Holmes, Marcus A Neubauer

Clin Breast Cancer· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advanced APMs and the emerging role of immuno-oncology agents: balancing innovation and value.
Michael V Seiden, Marcus Neubauer, Diana Verrilli

Am J Manag Care· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expectations in the care of lung cancer.
Rogerio Lilenbaum, Natasha B Leighl, Marcus Neubauer

Am Soc Clin Oncol Educ Book· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving incidence of code status documentation through process and discipline.
Marcus A Neubauer, Cynthia B Taniguchi, J Russell Hoverman

J Oncol Pract· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer.
Joyce O'Shaughnessy, Lee Schwartzberg, Michael A Danso, Kathy D Miller, Hope S Rugo, Marcus Neubauer

J Clin Oncol· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Opening the black box: the impact of an oncology management program consisting of level I pathways and an outbound nurse call system.
J Russell Hoverman, Ira Klein, Debra W Harrison, Jad E Hayes, Jody S Garey, Marcus Neubauer

J Oncol Pract· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial.
Edward S Kim, Marcus Neubauer, Allen Cohn, Lee Schwartzberg, Lawrence Garbo

Lancet Oncol· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy.
Samir E Witta, Robert M Jotte, Katrik Konduri, Marcus A Neubauer, Alexander I Spira

J Clin Oncol· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer.
Alexander I Spira, Nicholas O Iannotti, Michael A Savin, Marcus Neubauer, Nashat Y Gabrail

Clin Lung Cancer· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.
Allen L Cohn, Grace C Shumaker, Pankaj Khandelwal, David A Smith, Marcus A Neubauer

Clin Colorectal Cancer· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benchmarks for value in cancer care: an analysis of a large commercial population.
Michael Kolodziej, J Russell Hoverman, Jody S Garey, Janet Espirito, Sheetal Sheth, Marcus A Neubauer

J Oncol Pract· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Creating a process to standardize regimen order sets within an electronic health record.
Leslie T Busby, Sheetal Sheth, Jody Garey, Aimee Ginsburg, Thomas Flynn, Marcus A Neubauer

J Oncol Pract· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pathways, outcomes, and costs in colon cancer: retrospective evaluations in two distinct databases.
J Russell Hoverman, Thomas H Cartwright, Debra A Patt, Janet L Espirito, Matthew P Clayton, Marcus A Neubauer

J Oncol Pract· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis